Category Archives: Shanxi

Shanxi Healthcare Security Bureau to Implement National TCM Alliance Fourth Batch and Second Batch Follow‑up VBP Results From Oct 15 – Province‑Wide Execution Through 2028 With Listing Suspensions and Price Risk Flags for Non‑Winning Products

Implementation Snapshot

Item	Detail
Authority	Shanxi Provincial Healthcare Security Bureau, China
Document	Jin Yi Bao Han [2026] No. 72 – Notice on implementing national TCM alliance winning results
Batches	National TCM Procurement Alliance Fourth Batch (ZCYLM‑2026‑1) and Second Batch follow‑up (ZCYLM‑2026‑2)
Institutional Scope	All provincial public medical institutions (incl. military), participating insurance‑designated private institutions and designated pharmacies
Execution Date	15 October 2026, province‑wide
Procurement Cycle	15 Oct 2026 – 31 Dec 2028; first year through 14 Oct 2027; agreements signed annually, renewal volumes in principle no less than prior year
Supply Rule	Winning enterprises supply at winning prices beyond agreed volumes until cycle expiry

Price Execution & Platform Measures

Listing & Tripartite Agreements: The provincial drug and device procurement center will list winning products at winning prices and organize tripartite contracts among winning manufacturers, distributors and medical institutions per volume‑based procurement (VBP) rules.
Listing Suspensions: Within the same procurement group (administration route), products already listed provincially but not declared in winning enterprises’ “supply lists” will be suspended from listing — except products containing both natural bezoar and natural musk.
Price Risk Flags: Non‑winning products, and natural bezoar/musk products outside winning supply lists, will carry price risk warning markers on the platform.

Usage, Assessment & Monitoring Requirements

Rational Use Mandate: Medical institutions must prioritize winning products and fulfill agreed volumes, while avoiding concentrated bulk purchasing of winners and any “one‑size‑fits‑all” cutoff of non‑winning products; where winning products force brand switches for patients, dedicated department and staff training plus patient explanation work is required.
Assessment Design: Winning‑product procurement and use enter institutional performance assessments; non‑winning products priced below the lowest winning price are excluded from execution assessment; drug volumes in special‑need and international medical services (outside basic insurance payment) are excluded from monitoring; same‑name/dosage/specification products of one winning enterprise with compliant price differentials across package sizes may be assessed on a merged basis — a rule extendable to other national TCM alliance batches.
Supply & Compliance Monitoring: Insurance departments will monitor winning‑enterprise supply and hospital execution, using reminders and accountability interviews for supply shortfalls, with escalation reporting for major quality or supply problems; institutions showing below‑schedule progress, markedly low winning‑product share, or “buying high, not low” will face notification, with further measures for inadequate rectification.
Policy Coordination: Procurement, supply assurance, payment settlement, insurance reimbursement and quality management responsibilities are assigned across relevant units to ensure the results take full effect.

Sector Background

National TCM Alliance: Led cross‑province centralized procurement of traditional Chinese patent medicines, extending VBP beyond chemical drugs into the TCM segment — one of China’s largest pharmaceutical categories by prescription volume.
Follow‑up (接续) Procurement: Successor rounds that re‑tender expiring batch agreements, stabilizing prices and supply continuity for previously procured products.
Supply‑List Mechanism: Winning enterprises declare distributable product lists that determine which comparable items remain listed — a lever to steer hospital purchasing toward winners without formally banning alternatives.

Market Impact & Outlook

Price Reset for TCM Makers: From 15 October, winning manufacturers gain contracted volume across Shanxi at alliance‑set prices, while non‑winners face platform flags or suspension — reshaping competitive positions per procurement group.
Volume Security for Winners: The “winning price applies beyond agreed volumes until cycle end” clause protects hospitals’ upside demand without further negotiation, and annual renewals anchored at no‑less‑than‑prior volumes give winners multi‑year visibility.
Compliance Watchpoints: Distributors and manufacturers should verify supply‑list inclusion, prepare tripartite contracts, and track the natural bezoar/musk exemption — the notable carve‑out reflecting scarcity‑driven pricing in premium TCM materials.
Replication Signal: The merged‑assessment approach and its extension to other alliance batches may preview softer, more practical execution metrics for TCM VBP nationwide.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of national TCM alliance procurement results in Shanxi, including price adjustments, listing actions and procurement volumes. Actual execution depends on platform operations, enterprise supply performance, institutional compliance and assessment outcomes, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ybj.shanxi.gov.cn/xxfb/xxgkml/202609/t20260918_10222979.html

Shanxi Clarifies Medical Service Pricing Rules for Public Hospitals

Leave a reply

Taiyuan, Sept 7, 2026 — The Shanxi Provincial Medical Security Bureau has issued a formal interpretation of its medical service pricing policy (Notice No. 9 of 2026), setting out detailed billing rules for public medical institutions across ten areas—from price-item design and “service output” definitions to surcharge stacking, pricing units and the separation of consumables from clinical services.

Policy Snapshot

Attribute	Detail
Document	Interpretation of Price Policy for Medical Service Projects
Reference	Shanxi Medical Security Bureau Notice No. 9 of 2026
Issuing body	Shanxi Provincial Medical Security Bureau
Date	Sept 7, 2026 (proactively disclosed)
Scope	Billing and price-item application across public medical institutions in Shanxi
Core principle	Price items anchored to “service output,” not to devices or consumables
Key reforms	Separation of technology and consumables (“技耗分离”); separation of drugs and consumables (“药耗分离”)

Policy Context

The interpretation clarifies how hospitals should apply China’s new project-establishment guidelines for medical service prices. Under the framework, price items are created only where a distinct clinical service output exists: identical outputs from different techniques or pathways must map to a single item, complete procedures cannot be unbilled into steps, and no item may be established around a device or consumable—for instance, arrhythmia ablation is priced as one item regardless of whether radiofrequency, cryo, chemical or pulsed-field energy is used.

The document defines service output across four dimensions—core clinical outcomes, tangible auxiliary outputs such as test reports, patient-experience outputs, and auxiliary operations billed under an “A+B” (procedure plus add-on) model—and lays out anti-duplication rules with concrete examples: CT plain and enhanced scans may stack only when both are actually performed; ICU nursing fees already embed oral and perineal care; manual release cannot be billed alongside same-site traditional Chinese medicine tuina massage.

On pricing units, the bureau details per-session, per-site and progressive-base calculations—ambulance transport charges a base fare covering 4 kilometers plus 3 yuan per additional kilometer, while nerve-block anesthesia bills a two-hour base of 379 yuan plus 149 yuan per additional hour. Surcharge items within the same sequence cannot stack, though cross-sequence surcharges (for example, chief-physician and pediatric add-ons) may combine. The pediatric surcharge applies strictly through age six—until the day before a child’s seventh birthday—and “newborn” items are limited to the first 28 days of life.

Market Impact Analysis

The interpretation operationalizes one of the most consequential shifts in China’s healthcare payment system: the “separation of technology and consumables” principle, which purifies service prices to reflect clinical labor value while making consumable prices explicit and independently managed. By decoupling medical consumables from service items, the policy ends the legacy rule that “no service item, no consumable charge,” laying groundwork for a provincial medical insurance consumables catalog and extending drug-pricing tools—volume-based procurement and catalog management—to devices and disposables.

For hospitals, the document functions as a compliance manual: it resolves recurring billing ambiguities (whether examination fees may be layered onto consultation fees, how mapping items fold into price composition, when re-performed procedures may be billed again) that directly affect revenue integrity under medical insurance audits. The explicit anti-duplication and “basic material consumption” rules—where inclusive but non-analogical interpretation bars separate billing for items like soda lime while allowing distinct high-value devices such as pulse lavage systems—signal tighter scrutiny of unbundling practices.

Provincial-level guidance of this granularity is also a bellwether: as national project-establishment guidelines roll out across China, other provinces are expected to publish similar interpretations, making Shanxi’s framework a reference point for hospital billing systems, medical insurance enforcement and health-economics planning nationwide.

Forward-Looking Statement

Public medical institutions in Shanxi are expected to align billing systems, staff training and internal audit procedures with the interpretation immediately, as the document serves as the operational basis for price execution and insurance fund supervision. Market watchers will monitor whether the clarifications accelerate adoption of the standalone consumables pricing system and how the “service output” consolidation approach shapes future pricing of emerging technologies—including AI-assisted diagnostics and xenotransplantation, which the document already flags as non-separately-billable extensions of existing items. Similar interpretations from other provincial medical security bureaus are anticipated as the national pricing reform deepens toward mid-2027.-China Health Reform Pulse

Policy Source: https://ybj.shanxi.gov.cn/xxfb/xxgkml/202609/t20260907_10215759.html

Shanxi Seeks Input on Drug Vigilance Inspection Rules

Leave a reply

Taiyuan, Aug 26, 2026 — Shanxi Province’s drug regulator opened a month-long public consultation on revised pharmacovigilance inspection standards, aiming to tighten post-market safety oversight and compel drug marketing authorization holders to fortify their adverse-event monitoring systems.

Policy Snapshot

Attribute	Detail
Issuer	Shanxi Provincial Drug Administration
Document	Detailed Rules for Drug Vigilance Inspection in Shanxi Province (Draft for Comments)
Legal basis	Drug Administration Law; Drug Administration Law Implementing Regulations (State Council Order No. 828)
Purpose	Establish pharmacovigilance system; standardize provincial inspections; enforce MAH pharmacovigilance responsibilities
Comment deadline	Sept 25, 2026
Submission	shengjuajc@163.com (subject line: “Detailed Rules for Drug Vigilance Inspection—Comments”)
Contact	0351-8383669

Key Provisions

The draft revision outlines inspection protocols for drug marketing authorization holders operating in Shanxi, requiring robust systems for adverse drug reaction monitoring, risk identification, and post-market safety signal management. The rules align with national mandates under the Drug Administration Law and its implementing regulations, translating federal pharmacovigilance obligations into enforceable provincial inspection criteria.

Market Impact Analysis

The consultation signals intensified provincial scrutiny of drug safety systems beyond Beijing’s baseline requirements. For pharmaceutical companies and local marketing authorization holders, the forthcoming rules will likely standardize audit frequencies, documentation standards, and corrective action timelines for pharmacovigilance lapses. The one-month comment window suggests regulators intend to finalize the standards by the fourth quarter of 2026, leaving limited time for industry to shape provisions on inspection scope and penalty thresholds.

Smaller domestic generics manufacturers with limited pharmacovigilance infrastructure face the steepest compliance climb, while multinational firms with established global safety databases may benefit from clearer local rules that reduce interpretive ambiguity during provincial audits. The explicit focus on holding marketing authorization holders accountable reinforces China’s post-2020 regulatory pivot toward lifecycle responsibility rather than pre-market approval alone.

Forward-Looking Statement

Industry analysts expect Shanxi’s draft to serve as a template for neighboring provinces drafting localized pharmacovigilance inspection frameworks, potentially triggering a wave of regional rulemaking before year-end. Marketing authorization holders should use the comment period to clarify inspection scope boundaries and propose proportionality standards for small-volume products. Final rules are anticipated by late October or November 2026, with inspections likely commencing in early 2027. Companies are advised to conduct preemptive pharmacovigilance system audits against the draft criteria to avoid regulatory action once the rules take effect.-China Health Reform Pulse

Policy Source: https://yjj.shanxi.gov.cn/xxfb/gsgg/202608/t20260828_10209283.shtml